| Literature DB >> 35052680 |
Javier Echave1, Paz Otero1, Paula Garcia-Oliveira1,2, Paulo E S Munekata3, Mirian Pateiro3, Jose M Lorenzo3,4, Jesus Simal-Gandara1, Miguel A Prieto1,2.
Abstract
Seaweeds are a typical food of East-Asian cuisine, to which are alleged several beneficial health effects have been attributed. Their availability and their nutritional and chemical composition have favored the increase in its consumption worldwide, as well as a focus of research due to their bioactive properties. In this regard, seaweed proteins are nutritionally valuable and comprise several specific enzymes, glycoproteins, cell wall-attached proteins, red algae phycobiliproteins, lectins, peptides, or mycosporine-like amino acids. This great extent of molecules has been reported to exert significant antioxidant, antimicrobial, anti-inflammatory, antihypertensive, antidiabetic, or antitumoral properties. Hence, knowledge on algae proteins and derived compounds have gained special interest for the potential nutraceutical, cosmetic or pharmaceutical industries based on these bioactivities. Although several molecular mechanisms of action on how these proteins and peptides exert biological activities have been described, many gaps in knowledge still need to be filled. Updating the current knowledge related to seaweed proteins and peptides is of interest to further asses their potential health benefits. This review addresses the characteristics of seaweed protein and protein-derived molecules, their natural occurrence, their studied bioactive properties, and their described potential mechanisms of action.Entities:
Keywords: bioactive; molecular mechanisms; peptides; protein; seaweed
Year: 2022 PMID: 35052680 PMCID: PMC8773382 DOI: 10.3390/antiox11010176
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Protein content and aminoacidic composition of seaweeds.
| Species | Protein (% dw) | AA Composition (g/100 g Protein) | Free AA (mg/g) | EAA (%TAA) | Ref. |
|---|---|---|---|---|---|
| Rhodophyceae | |||||
| 12.5 | 4.7 Thr, 6.1 Val, 3.6 Iso, 5.9 Leu, 0.5 Tyr, 3.8 Phe, 4.6 His, 5.6 Lys, 2.7 Met, 4.1 Cya, 3 Tau, 10.2 Asp, 5 Ser, 15.5 Glu, 5.8 Gly, 6.3 Ala, 2.1 Cys, 6 Arg, 4.4 Pro. | 112.18 | 37.7 | [ | |
| 16.2 | 7.6 Ala, 6.8 Arg, 12.5 Asp, 12.3 Glu, 6.5 Gly, 1.6 His, 4 Ile, 7 Leu, 7.7 Lys, 2.2 Met, 5 Phe, 5.5 Pro, 6 Ser, 5.3 Thr, 3.4 Tyr, 6.6 Val | 124 | 24.8 | [ | |
| 28.7 | 3.3 Asp, 3.1 Glu, 3 Ala, 2.3 Arg, 1.8 Gly, 1.6 Ser, 1 Tyr, 0.9 Pro, 1.1 Phe, 0.6 His, 1.1 Ile, 2.2 Leu, 2.2 Lys, 0.5 Met, 1.2 Thr, 1.2 Val | 286.6 | 39.8 | [ | |
| 33.2 | 6.6 Asp, 4.6 Ser, 8.3 Glu, 7.5 Gly, 2.2 His, 9 Arg, 5 Thr, 8 Ala, 3.8 Pro, 1.3 Met, 0.4 Cys, 4.8 Val, 2.3 Lys, 3.4 Ile, 5.3 Leu, 7.8 Phe, 2.9 Tyr | n.a. | 41.0 | [ | |
| 24.6 | 12.2 Asp, 10.5 Glu, 6.1 Ser, 1.2 His, 8.8 Gly, 5.9 Thr, 6.1 Arg, 12.5 Ala, 3.9 Pro, 2.5 Tyr, 3.7 Phe, 5.8 Val, 1.6 Met, 1.9 Cys, 2.7 Ile, 0.6 Trp, 7.3 Leu, 6 Lys | n.a. | 35.0 | [ | |
| 35.2 | 5.5 Thr, 6.2 Val, 4.5 Ile, 6.9 Leu, 2.7 Tyr, 4.3 Phe, 2.1 His, 5.3 Lys, 3.3 Met, 2.9 Cya, 1.2 Tau, 12 Asp, 5.1 Ser, 12.1 Glu, 5.2 Gly, 7.5 Ala, 0.7 Cys, 6.5 Arg, 5.6 Pro | 226.2 | 40.9 | [ | |
| 19.5 | 3.6 Asp, 3.1 Glu, 4.6 Ser, 1.4 Thr, 1.8 His, 0.3 Gln, 0.3 Tau, 2.8 Arg, 0.4 Ala, 1.4 Tyr, 3.4 Lys, 2 Val, 0.2 Met, 1.5 Phe, 1.6 Ile, 2 Leu, 1.5 Hyp | 72.8 | 46.7 | [ | |
| 24.3 | 4.8 Asp, 4.5 Glu, 3.9 Ser, 2.7 Thr, 3.7 His, 0.3 Gly, 0.1 Gln, 0.4 Tau, 2.4 Arg, 1.1 Ala, 1.7 Tyr, 3 Lys, 2.6 Val, 0.5 Met, 1.5 Phe, 2.1 Ile, 2.5 Leu, 1 Hyp | 66.9 | 47.9 | [ | |
| 20.7 | 13.6 Asp, 12.1 Glu, 2.7 Ser, 2.5 Gly, 0.9 His, 3.7 Arg, 5.7, Thr, 0.7 Ala, 15.8 Pro, 2 Tyr, 2.2 Val, 1.9 Met, 16.5 Ile, 2.2 Phe, 2.7 Lys | n.a. | 41.6 | [ | |
| 13.7 | 1.1 Asp, 1.5 Glu, 0.7 Ser, 1.1 His, 0.4 Gly, 0.6 Thr, 0.6 Arg, 0.6 Ala, 0.3 Tyr, 0.7 Val, 1.8 Met, 0.7 Cys, 0.8 Ile, 0.4 Leu, 1 Phe, 0.6 Lys | n.a. | 42.8 | [ | |
| 18.7 | 1.4 Arg, 0.1 His, 1.3 Lys, 1 Thr, 0.9 Ile, 1.2 Leu, 1 Val, 0.3 Met, 0.9 Phe, 0.9 Pro, 1.2 Ala, 0.6 Tyr, 2.1 Asp, 2.5 Glu, 1.3 Gly, 1.2 Ser | n.a. | 45.6 | [ | |
| 21 | 1.9 Ala, 0.8 Gly, 1.4 Val, 1.6 Leu, 0.9 Ile, 0.7 Thr, 0.8 Ser, 1.5 Pro, 2 Asp, 0.1 Met, 1.6 Glu, 1 Phe, 1.2 Lys, 0.3 His, 0.7 Tyr | n.a. | 44.1 | [ | |
| Phaeophyceae | |||||
| 8.4 | 3.6 Thr, 6.2 Leu, 3.7 Ile, 4 Phe, 4.1 Lys, 1.3 Met, 2.1 Tyr, 2.3 Trp, 8.2 Asp, 29.7 Glu, 3.5 Cys, 1.3 His, 4.2 Gly, 3.9 Pro, 7.9 Ala, 3.8 Arg | 74.9 | 27.8 | [ | |
| 12.9 | 6.1 Thr, 5.8 Val, 2.1 Met, 5 Ile, 8.6 Leu, 5.4 Phe, 8 Lys, 1.9 His, 5.5 Arg, 3.2 Tyr, 16.7 Asn, 6.3 Ser, 19.7 Glu, 6.5 Gly, 9.8 Ala, 5.7 Pro, 2 Cys | 119 | 40.9 | [ | |
| 11.8 | 5.2 Arg, 7.2 Glu, 5.5 Ser, 2.7 Thr, 1.6 His, 0.1 Gln, 0.7 Tau, 1.5 Arg, 0.7 Ala, 3.7 Lys, 2.2 Val, 0.2 Met, 0,1 Trp, 1.2 Phe, 1,9 Ile, 1.8 Hyp | 130 | 38.7 | [ | |
| 9.7 | 5.6 Asp, 12.1 Glu, 11.4 Ser, 7.4 Gly, 3.2 His, 11.7 Arg, 10.8 Thr, 4 Ala, 6.9 Pro, 7.7 Tyr, 11.4 Val, 6.3 Met, 15.4 Leu, 15.3 Ile, 9.8 Phe, 12.5 Lys | n.a. | 63.5 | [ | |
| 4.5 | 6.9 Ala, 4.4 Arg, 16 Asp, 16.3 Glu, 5.9 Gly, 1.4 His, 4.4 Ile, 7.5 Leu, 5.5 Lys, 2 Met, 5.3 Phe, 4.5 Pro, 5.4 Ser, 5.8 Thr, 2.9 Tyr, 6 Val | 35 | 29.2 | [ | |
| 9.4 | 4.1 Asp, 7.2 Glu, 3.9 Ser, 1.9 Thr, 1.1 His, 0.7 Tau, 1.7 Arg, 1.5 Ala, 0.9 Tyr, 3.3 Lys, 1.9 Val, 0.4 Met, 0.1 Trp, 1.2 Phe, 1.6 Ile, 2.3 Leu, 1.6 Hyp | 133 | 39.2 | [ | |
| 12 | 11 Ala, 4.8 Arg, 13.4 Asp, 13.8 Glu, 5.6 Gly, 1.6 His, 4.4 Ile, 7.9 Leu, 5.9 Lys, 2.4 Met, 5.2 Phe, 4.5 Pro, 5 Ser, 5.3 Thr, 3.1 Tyr, 6 Val | 98 | 32.7 | [ | |
| 8.9 | 3.6 Thr, 3.7 Val, 1.7 Met, 2.9 Iso, 5.2 Leu, 3.3 Phe, 3.9 Lys, 1.3 His, 3.3 Arg, 1.7 Tyr, 8 Asn, 3.5 Ser, 15 Glu, 3.9 Gly, 8.4 Ala, 3.1 Pro | 73.2 | 39.9 | [ | |
| 16.5 | 4.3 Asp, 7.6 Glu, 5.8 Ser, 2.4 Thr, 1.4 His, 0.2 Gly, 0.6 Tau, 2.7 Arg, 3.4 Ala, 1.5 Tyr, 2.8 Lys, 2.5 Val, 0.7 Met, 1.7 Phe, 2 Ile, 3 Leu, 0.9 Hyp | 64.7 | 37.2 | [ | |
| 16.8 | 7.5 Asp, 4.1 Ser, 12 Glu, 6.5 Gly, 1.7 His, 8.8 Arg, 2.9 Thr, 9.7 Ala, 4.4 Pro, 0.1 Met, 0.3 Cys, 5.8 Val, 3.9 Lys, 5 Ile, 8.6 Leu, 4.8 Phe, 2 Tyr | n.a. | 23.4 | [ | |
| Chlorophyceae | |||||
| 23.3 | 6.1 Asp, 5.2 Glu, 7.8 Ser, 2 Thr, 3.3 His, 0.2 Gly, 0.2 Gln, 0.3 Tau, 3.7Arg, 1.1 Ala, 1.9 Tyr, 3.2 Lys, 3.5 Val, 0.6 Met, 0.1 Trp, 2.4 Phe, 2.6 Ile, 3.5 Leu, 1.4 Hyp | 116.2 | 43.6 | [ | |
| 17.4 | 3.1 Ile, 5.2 Leu, 3.7 Lys, 1.5 Met, 1.1 Cys, 3.3 Phe, 2.2 Tyr, 5 Thr, 5.6 Val, 1.4 His, 13 Asp, 9.4 Glu, 4.3 Pro, 6.1 Ser, 7.8 Gly, 12.3 Ala, 4.6 Arg | n.a. | 30.8 | [ | |
| 9.6 | 12.5 Asp, 9.4, 8.4 Ala, 6 Arg,6 Gly, 5.5 Ser, 3.2 Tyr, 4.4 Pro, 1 Hyp, 5.7 Phe, 2.9 His, 4.4 Ile, 7.8 Leu, 4.7 Lys, 1.3 Met, 4.8 Thr, o.4 Trp, 6.8 Val | 4.9 | 40.8 | [ | |
| 16.4 | 3.7 Ile, 6.7 Leu, 4.2 Lys, 1.6 Met, 0.4 Cys, 4 Phe, 2.1 Tyr, 4.7 Thr, 6.2 Val, 1.8 His, 12.3 Asp, 9 Glu, 5.3 Pro, 5.9 Ser, 10.7 Gly, 14.2 Ala, 3.6 Arg | n.a. | 33.6 | [ | |
| 15 | 8.4 Ala, 6.4 Arg, 12.1 Asp, 13.5 Glu, 6.4 Gly, 1.8, His, 4.2 Ile, 8 Leu, 5.5 Lys, 2.2 Met, 5.6 Phe, 4.7 Pro, 5.5 Ser, 5.5 Thr, 3.5 Tyr, 6.4 Val | 106.1 | 36.9 | [ | |
| 17.3 | 3.5 Ile, 6-8 Leu, 3.7 Lys, 1.5 Met, 4 Phe, 2 Tyr, 5 Thr, 6.3 Val, 1.7 His, 17.2 Asp, 10.9 Glu, 3.6 Pro, 6.4 Ser, 8.8 Gly, 11.8 Ala, 3.3 Arg | n.a. | 32.7 | [ | |
| 10.8 | 0.8 Asp, 1 Glu, 0.5 Ser, 0.09 His, 0.5 Gly, 0.5 Thr, 0.4 Arg, 0.6 Ala, 0.3 Tyr, 1.4 Val, 0.9 Met, 0.1 Cys, 0.4 Ile, 0.7 Leu, 0.4 Phe, 0.5 Lys | n.a. | 44.7 | [ | |
| 12 | 5.5 Ala, 6.5 Arg, 15.3 Asp, 15.3 Glu, 6.7 Gly, 1.4 His, 3.6 Ile, 7 Leu, 7.4 Lys, 1.8 Met, 4.5 Phe, 5.7 Pro, 4.3 Ser, 5.1 Thr, 4.3 Tyr, 5.8 Val | 95.9 | 38.1 | [ | |
Notes and Abbreviations. AA: amino acids; EAA: Essential amino acids; TAA: Total amino acids; n.a.: Not analyzed. Amino acids: alanine (Ala); aspartic acid (Asp); arginine (Arg); asparagine (Asn); glutamic acid (Glu); glutamine (Gln); glycine (Gly); hydroxyproline (Hyp); histidine (His); isoleucine (Ile); leucine (Leu); lysine (Lys); methionine (Met); phenylalanine (Phe); proline (Pro); serine (Ser); taurine (Tau); tryptophan (Trp); tyrosine (Tyr); threonine (Thr); valine (Val).
Figure 1Chemical structure of the chromophore group of R-phycoerythrin, some relevant mycosporine-like amino acids, and bioactive peptides isolated from seaweed protein hydrolysates. Peptide sequences and source are presented in Table 3.
Figure 2Schematic representation of seaweed protein hydrolysis into peptides. The hydrolyzation process usually involves the action of proteases and the adjustment of reaction parameters. Among the peptides produced by protein hydrolyzation, some display bioactive properties.
Figure 3Summary of reported mechanisms of action of several SPs and BAPs. Their location with respect to the bilayer membrane represents that these effects are inducted inside, outside the cell, or on the cell surface. Abbreviations: PBPs: phycobiliproteins; MAAs: mycosporine-like amino acids; BAPs: bioactive peptides; ROS: reactive oxygen species; IL-1β: interleukin-1β; TNF-α: tumor necrosis factor- α; COX-2: cyclooxygenase-2; iNOS: inducible nitric oxide synthase; NF-κB: nuclear factor- κB; DPP-IV: dipeptidyl peptidase-IV; GLP-1: glucagon-like peptide-1; ACE: angiotensin I-converter enzyme.
Reported bioactive proteins from seaweeds and their mechanisms of action.
| Species | Protein(s) | Bioactivity | Mechanism of Action | Ref. |
|---|---|---|---|---|
| Rhodophyceae | ||||
| Lectin | In vivo, antiviral | Mannose-binding lectin binds with viral envelope GPs, inhibiting viral infection of HIV-1, HSV, and HPV | [ | |
| In vitro, antiviral | Mannose-binding lectin binds with Spike GPs, inhibiting viral infection of SARS-CoV | [ | ||
| In vitro, antiviral | Griffithsin and synthetic polymers showed high virucidal activity in cell-associated HIV-1 and in the presence of seminal and vaginal simulants. Blocking of CD4+ viral binding | [ | ||
| Lectin | In vitro, antiviral | Mannose-binding lectin binds with viral envelope GPs, inhibiting viral infection of Influenza H1N1 and HSV1/2 | [ | |
| Lectin | In vitro, antiviral | Mannose-binding lectin binds to Influenza hemagglutinin and HIV GP gp120, avoiding infection | [ | |
| Lectin | In vitro, antimicrobial | Growth inhibition of | [ | |
| Lectin | In vivo, antimicrobial | There was >50% mortality reduction in 100 μg/mL treated shrimp, related with agglutination of | [ | |
| PBPs | In vitro, antifungal | Dosage of 0.3 mg/mL inhibited | [ | |
| GP | In vitro, anti-inflammatory | Inhibition of TLR4 and ERK1/2 activation, inhibition of NF-κB release | [ | |
| Lectin | In vivo, anti-inflammatory | Paw edema reduction against several pro-inflammatory agents. Reduction in TNF-α, IL-1β levels, and neutrophil migration. Increased glutathione levels | [ | |
| Lectin-rich extract | In vivo, anti-inflammatory | Decreased mucin synthesis, leucocyte infiltration, and TNF-α, NF-κB, IL-4, MMP-9, EGFR levels in asthmatic rats | [ | |
| Lectin | In vivo, anti-inflammatory | Reduced peritonitis and paw edema in treated mice. Reduction in TNF-α, IL-1β, MPO levels, and neutrophil migration. Better results than the positive control | [ | |
| Lectin | In vitro, antitumor | Apoptosis induction. Bcl-2 downregulation, upregulation of caspases 3,8,9 | [ | |
| PE | In vitro, antitumor | Apoptosis induction. Increased caspase 3/9 and p53 expression | [ | |
| R-PE | In vitro, antitumor | Apoptosis induction. Cell cycle arrest at G2/M phase, membrane blebbing, and >80% cell deaths at 1 mg/mL | [ | |
| Lectin | In vitro, antitumor | Apoptosis induction. Increased caspase-3 expression, binding to mannose in human sarcoma cells. Complete cancer cell death at 2 μg/mL, but not in normal cells | [ | |
| Lectin | In vivo, wound healing | Induced greater inflammatory response, fibroblast proliferation, and collagen synthesis. Reduced wound size and faster closure in treated mice | [ | |
| Phaeophyceae | ||||
| Lectin | In vitro, antioxidant | Dosage of 1.6 mg/mL inhibited 77.23% DPPH; 4 mg/mL inhibited 68.97% ABTS | [ | |
| GP | In vitro, antioxidant | DPPH (IC50 = 0.12 mg/mL), ABTS (IC50 = 0.05 mg/mL), FRAP (IC50 = 0.3 mg/mL) and xanthine oxidase (70%, 0.2 mg/mL) inhibition | [ | |
| GP | In vitro, antidiabetic | Rat intestinal (IC50 = 0.29 mg/mL) and yeast (IC50 = 0.11 mg/mL) α-glucosidase inhibition. Retained >60% of inhibitory activity after thermal treatments | [ | |
| Chlorophyceae | ||||
| 2 lectins | In vitro, antibiofilm | Binding to monosaccharide residues of the biofilms with preference to α-linkages | [ | |
| Lectin | In vitro, antiviral | High mannose-binding lectin, bonded with Influenza H3N2 viral envelope hemagglutinin, preventing infection | [ | |
| Lectin | In vitro, antiviral | High mannose-binding lectin binds to Influenza hemagglutinin and HIV-1 GP gp120, avoiding infection | [ | |
| Lectin | In vivo, anti-inflammatory and antinociceptive | Analgesic effect as measured by paw licking time. Reduced neutrophil infiltration (65.9%), better than the positive control | [ | |
| Lectin | In vivo, anti-inflammatory and antinociceptive | Reduced levels of TNF-α, IL-1β, MPO, and leukocyte infiltration | [ | |
| Lectin | In vivo, anti-inflammatory | IL-1β, IL-6, TNF-α and COX-2. Lower neutrophil infiltration | [ | |
| GP | In vitro, antitumor | Apoptosis induction. Mitochondrial membrane alterations, caspase 3 and Bcl-2 genes upregulation | [ | |
Notes and abbreviations. GP: Glycoprotein; GPs: glycoproteins: PE: Phycoerythrin; PBP: Phycobiliprotein; DPPH: 2:2-diphenyl-1-picrylhydrazyl; ABTS: 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid); HIV: Human immunodeficiency virus; HSV: Herpes simplex virus; SARS-CoV: Severe acute syndrome-coronavirus; IC50: Minimum half-inhibitory concentration; IL: Interleukin; TNF-α: Tumor necrosis factor-α; EGFR: Epidermal growth factor receptor; NF-κB: Nuclear factor κb; TLR: Toll-like receptor; ERK: Extracellular receptor kinase; MPO: Myeloperoxidase; MMP: Matrix-metallopeptidase.
Bioactive peptides and hydrolysates obtained from seaweed proteins.
| Species | Hydrolysis | Sequence/s | Bioactivity | Results | Ref. |
|---|---|---|---|---|---|
| Rhodophyceae | |||||
| Trypsin; E:S (1:25), 37 °C, pH 8, 8 h | QVEY | In vitro, antihypertensive | ACE inhibitory activity. IC50= 0.25 mg/mL | [ | |
| α-Chymotrypsin; E:S (1:25), 37 °C, pH 8, 2 h | ELWKTF | In vitro, antioxidant | DPPH radical scavenging. EC50 = 1.51 mg/mL | [ | |
| Pepsin; E:S (1:100), pH 2, 45 °C, 4 h | GGSK, ELS | In vitro, antidiabetic | α-Amylase inhibition. IC50(GGSK) = 0.8 mg/mL, IC50(ELS)= 0.9 mg/mL | [ | |
| Alcalase® and Flavourzyme®; E:S (1:100), 50 °C, pH 7, 4 h | DYYLR, AGFY, YLVA, AFIT, MKTPITE, TYIA, LDLW | In vitro, antioxidant | Most antioxidant on ORAC assay: IC50(AFIT) = 0.4 μg/mL, IC50(MKTPITE) = 0.007 mg/mL | [ | |
| DYYLR, AGFY, YLVA, TYIA | In vitro, antihypertensive | Most inhibiting BAPs: IC50(TYIA) = 0.04 mg/mL, IC50(TYIA) = 0.07 mg/mL | [ | ||
| YLVA | In vitro, antidiabetic | DPP-IV inhibition, IC50 = 0.2 mg/mL | [ | ||
| Prolyve®; E:S (1:100), 50 °C, pH 8, 2 h | n.a., increased production of <1 kDa peptides | In vitro, antioxidant | ORAC (IC50 = 2.7 mmol TE/g), DPPH (IC50 = 0.2 mmol TE/g), FRAP (IC50 = 0.4 mmol TE/g) | [ | |
| Chemical synthesis | IY, MKY, AKTSY, LRY | Clinical trial, antihypertensive | Blood pression reduction from 157/95 to 142/86 mmHg with 1.8 g/day for 35 days | [ | |
| Pepsin; E:S (1:40), pH 2, 45 °C, 2 h | NMEKGSSSVVSSRM | Ex vivo, anticoagulant | Blood clotting retardation; IC50 = 4.49 μg/mL | [ | |
| Chemical synthesis | “PPY” peptide | In vitro, antitumor | Doses ≥125 ng/mL induced autophagy and apoptosis in MCF-7 cells via the mTOR pathway | [ | |
| Chemical synthesis | “PPY” peptide | In vitro, anti-inflammatory | Doses ≥250 ng/mL inhibited expression of inflammatory cytokines in murine macrophages | [ | |
| Alkaline protease; E:S (1:40), 55 °C, pH 9.5, 2 h | n.a., ~2.4 kDa peptides | In vitro, antihypertensive | ACE inhibitory activity. IC50 = 1.2 mg/mL | [ | |
| In vitro, anticoagulant | Antiplatelet aggregation. 2.8 mg/mL achieved 18.7% inhibition | [ | |||
| Trypsin; E:S (1:20), 50 °C, pH 8, 4 h | n.a., >400 Da peptides | In vitro, antioxidant and anti-inflammatory | DPPH (IC50 = 2.8 mg/mL), ABTS (IC50 = 2.4 mg/mL); upregulation of IL10 at 0.1 mg/mL | [ | |
| Fungal protease; E:S (1:20), 55 °C, pH 4.3, 3 h and Flavourzyme®; E:S (1:50), 55 °C, pH 7, 4 h | n.a. | In vitro, anti-inflammatory | Upregulation of IL-10 in murine spenocytes, macrophages and lymphocytes at ≥0.01 mg/mL | [ | |
| Chymotrypsin; E:S (1:20), pH 8, 30 °C, 24 h | 33 BAPs < 10 kDa | In vitro, antioxidant and antihypertensive | A <10 kDa fraction was the most bioactive at ≥0.75 mg/mL | [ | |
| Thermolysin; E:S (1:100), 70 °C, pH 7, 3 h | LRY | In vitro, antihypertensive | ACE inhibitory IC50 = 0.01 mg/mL | [ | |
| Papain; (20.7 U/ mg protein), 60 °C, pH 6, 24 h | IRLIIVLMPILMA | In vitro, antihypertensive | Renin inhibition. IC50 = 0.3 mg/mL | [ | |
| Chemical synthesis | IRLIIVLMPILMA | In vivo, antihypertensive | Systolic blood pressure reduction from 187 to 155 mm Hg at 50 mg/kg bw | [ | |
| Pepsin; E:S (1:200), pH 7.5, 37 °C, 90 min | ALLAGDPSVLEDR, VVGGTGPVDEWGIAGAR | In vitro, antihypertensive | ACE inhibition. IC50(ALLAGDPSVLEDR) = 57.2 mg/mL, IC50(VVGGTGPVDEWGIAGAR) = 66.2 μg/mL | [ | |
| Phaeophyceae | |||||
| Trypsin; E:S (1:20), pH 7, 30 °C, 24 h | EAESSLTGGNGCAK, IGNGGELPR, ILVLQSNQIR, ISAILPSR, ISGLIYEETR, LPDAALNR, MALSSLPR, QVHPDTGISK, TITLDVEPSDTIDGVK | In vitro, antimicrobial | Mix of all peptides (2.50 mg/mL) inhibited 40% | [ | |
| Pepsin; (80 U/g protein), 37 °C, pH 2, 2 h and Papain; (60 U/g protein), 50 °C, pH 7, 3 h | RWDISQPY | In vivo and in vitro, antihypertensive | Systolic blood pressure reduction from 170 to 150 mm Hg at 100 mg/kg bw; 25% endothelin-1 inhibition at 1.5 mg/mL | [ | |
| Alcalase®, papain, trypsin, and pepsin; 55 °C, pH 7.5. E:S and time not specified | KY, GKY, SKTY, AKY, AKY, AKYSY, KKFY, FY, KFKY | In vitro, antihypertensive | ACE inhibition. Hydrolysate of all combined proteases achieved IC50 = 0.6 mg/mL | [ | |
| Hot water; 93 °C, 20 min | YH, KW, KY, KF, VW, VF, IY, IW, VY | In vivo, antihypertensive | Systolic blood pressure reduction (25–34 mm Hg) by 10 mg/kg bw for 1 week | [ | |
| Pepsin; E:S (100:1), 45 °C, pH 2, 18 h | YH, KW, KY, KF, VW, VF, IY, IW, VY | In vivo, antihypertensive | Systolic blood pressure reduction (14–21 mm Hg) by 1 mg/kg bw for 1 week | [ | |
| Bromelain; (12 kU/g protein), 45 °C, pH 6, 4 h | KNFL | In vitro, antihypertensive | ACE inhibition. IC50 = 1.3 μg/mL | [ | |
| Chlorophyceae | |||||
| Trypsin; E:S (1:25), 37 °C, pH 8, 5 h | FGMPLDR, MELVLR | In vitro, antihypertensive | ACE inhibition. IC50(FGMPLDR, MELVLR) = 0.18 mg/mL | [ | |
| Pepsin; E:S (1:100), pH 2.0, 37 °C 20 h | IP, AFL | In vitro, antihypertensive | ACE inhibition. IC50(IP, AFL) = 0.2 mg/mL | [ | |
| Papain; E:S (1:100), 60 °C, pH 6, 24 h | 55 non-allergenic BAPs identified | In vitro, antihypertensive | ACE inhibition (93%) in >1 kDa hydrolysate fraction | [ | |
| Alcalase®; 2.9 kU/g protein, T not stated, pH 7.6, 90 min | PAFG | In vitro, antihypertensive | ACE inhibition. IC50 = 0.014 mg/mL | [ | |
| Thermolysin; E:S (1:50), 60 °C, pH 8.5, 16 h | FDGIP, AIDPVRA | In vitro, antihypertensive | ACE inhibition. IC50 (FDGIP)= 0.03 mg/mL, IC50 (AIDPVRA)= 0.04 mg/mL | [ | |
Abbreviations: E:S: Enzyme:substrate (w/w); IC50: Half-inhibitory concentration; TE: Trolox equivalents: BAPs: bioactive peptides; ACE: angiotensin I-converter enzyme; DPPH: 2,2-diphenyl-1-picrylhydrazyl; ABTS: (2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)); IL: interleukin; ORAC: oxygen radical absorbance capacity; FRAP: ferric reducing ability of plasma; mTOR: mammalian target of rapamycin.
Figure 4Potential applications of seaweed proteins, bioactive peptides, and Mycosporine-like amino acids considering their described bioactivities. Several properties of these molecules may be applied to diverse fields and industries in different formulations.